Open AccessEmerging ceftazidime-avibactam resistance against carbapenem resistant Escherichia coli and Klebsiella pneumoniae in Lebanon
Author(s) -
Ghena M Sobh,
Abdul Karim El Karaaoui,
Mira El Chaar,
George F. Araj
Publication year - 2021
Publication title -
the international arabic journal of antimicrobial agents
Language(s) - English
Resource type - Journals
ISSN - 2174-9094
DOI - 10.3823/858
Subject(s) - ceftazidime/avibactam , klebsiella pneumoniae , ceftazidime , escherichia coli , microbiology and biotechnology , enterobacteriaceae , carbapenem resistant enterobacteriaceae , drug resistance , avibactam , biology , carbapenem , antibiotics , bacteria , pseudomonas aeruginosa , biochemistry , genetics , gene
Ceftazidime-avibactam (CZA) has been introduced as a novel drug to essentially combat the rising trends of carbapenem resistant Enterobacteriaceae. In the absence of in vitro data about the activity of this drug against carbapenem resistant (CR) Escherichia coli and Klebsiella pneumoniae in Lebanon, this study was warranted.